Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02724020 · ClinicalTrials.gov registry record · Phase 2
MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
A Phase 2 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT02724020 is a Phase 2 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 96 participants.
The verdict
NCT02724020, a Phase 2 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of single-agent MLN0128 and the combination of MLN0128 + MLN1117 compared with everolimus in the treatment of participants with metastatic clear-cell renal cell carcinoma (mccRCC) that have progressed on vascular endothelial growth factor (VEGF)-targeted therapy.
Interventions
- DRUG Everolimus
- DRUG MLN0128
- DRUG MLN1117
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2016-06-30 |
| Est. Completion | 2020-10-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02724020
The ClinicalTrials.gov registry entry for NCT02724020 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Everolimus is the first listed.
NCT02724020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02724020 about?
NCT02724020 is a clinical study titled "MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma". The purpose of this study is to evaluate the efficacy and safety of single-agent MLN0128 and the combination of MLN0128 + MLN1117 compared with everolimus in the treatment of participants with metastatic clear-cell renal cell carcinoma (mccRCC) that have progressed on vascular endothelial growth fac...
What is the current status of trial NCT02724020?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2016-06-30. Estimated completion is 2020-10-13.
What interventions are being tested in trial NCT02724020?
The interventions under investigation include: Everolimus (DRUG), MLN0128 (DRUG), MLN1117 (DRUG).
Who is sponsoring clinical trial NCT02724020?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.